eligibility_summary
Adults with unresectable/locally advanced or metastatic: high-grade serous ovarian/fallopian tube/primary peritoneal (>=2 prior lines, platinum-refractory/resistant), primary pleural/peritoneal mesothelioma (non-sarcomatoid/non-WD papillary, >=1 line), or pancreatic ductal adenocarcinoma (>=1 line). Part 1: measurable/evaluable, Part 2: measurable (RECIST, mRECIST for meso). ECOG 0-1, biopsies required as assigned. Second malignancy allowed if non-interfering. Exclude CNS/leptomeningeal disease, low LVEF, talc pleurodesis <=3 mo, empyema/fistula, or HIPEC <=6 mo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06255665 evaluates JNJ-79032421, a T‑cell‑redirecting immunotherapy for advanced solid tumors (ovarian cancer, pleural/peritoneal mesothelioma, pancreatic ductal adenocarcinoma). Drug/intervention: JNJ-79032421, a T-cell redirecting antibody (bispecific T‑cell engager class), given as monotherapy with dose escalation then expansion to define RP2D. Mechanism of action: Binds mesothelin on tumor cells and recruits/activates T cells to form an immune synapse, triggering T‑cell cytotoxicity and cytokine release to lyse mesothelin‑expressing cancer cells. Cells/pathways targeted: Mesothelin-positive tumor cells, T lymphocytes via TCR signaling (CD3 complex) and downstream cytotoxic pathways. Phase: 1, primary goal: safety/tolerability and RP2D. Location: Spain. Status: Completed.